“We’re more than happy that Cecilia Jones, a frontrunner with intensive expertise in strategic finance and enterprise improvement within the life sciences sector, will probably be becoming a member of LogicBio as we enter an vital interval of development alternatives for the Firm,” mentioned Fred Chereau, LogicBio president and CEO. “We just lately introduced initiation of our part 1/2 SUNRISE medical trial for LB-001 within the remedy of methylmalonic acidemia and accomplished a profitable follow-on public providing. As we anticipate further key milestones in 2021, Cecilia will play a central position in supporting these vital initiatives and serving to LogicBio plan for a broad vary of recent improvement alternatives.”
“I’m thrilled to be becoming a member of LogicBio at this thrilling stage of the group as they work to increase the attain of genetic drugs,” mentioned Ms. Jones. “I stay up for becoming a member of the management workforce and making use of my expertise in international finance to assist the Firm maximize these alternatives within the years forward.”
Ms. Jones has greater than 20 years of expertise in consulting and monetary management roles with main pharmaceutical and biotechnology firms. She is presently vice chairman for R&D, worldwide medical and enterprise improvement finance, at Biogen, advising senior administration on funding prioritization to assist the Firm’s strategic targets. At Biogen she beforehand served as senior director company finance, the place she led international long-range planning and monetary evaluation of enterprise improvement and M&A alternatives, and director of rising markets finance, the place she supported Latin America, Asia Pacific and Japanese European markets. Previous to becoming a member of Biogen, Ms. Jones was director worldwide finance at Genzyme (now Sanofi Genzyme), the place she held numerous capabilities of accelerating duty inside worldwide finance. She acquired a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Enterprise College.
“On behalf of the board and administration workforce, I wish to lengthen our appreciation to Matthias Jaffe for his service as CFO at LogicBio throughout our childhood and for his dedication to working with our workforce as a advisor throughout 2021 to assist a easy transition,” Mr. Chereau added.
About LogicBio Therapeutics
LogicBio Therapeutics is devoted to extending the attain of genetic drugs with pioneering platforms. LogicBio’s proprietary genome enhancing expertise platform, GeneRide, allows the site-specific integration of a therapeutic transgene with out nucleases or exogenous promoters by harnessing the native technique of homologous recombination. LogicBio has acquired FDA clearance for the first-in-human medical trial of LB-001, an entirely owned genome enhancing program leveraging GeneRide for the remedy of methylmalonic acidemia. Affected person enrollment within the part 1/2 SUNRISE medical trial is anticipated to start in early 2021. As well as, LogicBio has a collaboration with Takeda to analysis and develop LB-301, an investigational remedy leveraging GeneRide for the remedy of the uncommon pediatric illness Crigler-Najjar syndrome.
LogicBio can also be growing a Subsequent Era Capsid platform to be used in gene enhancing and gene therapies. Information offered have proven that the capsids ship extremely environment friendly purposeful transduction of human hepatocytes with improved manufacturability with low ranges of pre-existing neutralizing antibodies in human samples. Prime-tier capsid candidates from this effort have demonstrated vital enhancements over benchmark AAVs presently in medical improvement. LogicBio is growing these extremely potent vectors for inside improvement candidates and probably for enterprise improvement collaborations.
Ahead Trying Statements
This press launch incorporates “forward-looking” statements inside the that means of the federal securities legal guidelines, together with with respect to the Firm’s administration transition, upcoming improvement milestones and the timing of affected person enrollment within the part 1/2 SUNRISE medical trial. These are usually not statements of historic info and are based mostly on administration’s beliefs and assumptions and on data presently out there. They’re topic to dangers and uncertainties that might trigger the precise outcomes and the implementation of the Firm’s plans to range materially, together with the dangers related to the initiation, value, timing, progress and outcomes of the Firm’s present and future analysis and improvement actions and preclinical research and potential future medical trials. These dangers are mentioned within the Firm’s filings with the U.S. Securities and Change Fee (SEC), together with, with out limitation, the Firm’s Annual Report on Kind 10-Ok filed on March 16, 2020, the Firm’s Quarterly Report on Kind 10-Q filed on Could 11, 2020, and the Firm’s subsequent filings with the SEC. Besides as required by regulation, the Firm assumes no obligation to replace these forward-looking statements publicly, even when new data turns into out there sooner or later.
SOURCE LogicBio Therapeutics, Inc.